Join the Fiasp group to help and get support from people like you.
Fiasp News
Stem Cell Treatment May Free Some With Type 1 Diabetes From Insulin
TUESDAY, June 24, 2025 — A single infusion of a new stem cell-based treatment may have helped 10 out of 12 people with severe type 1 diabetes stop using insulin, researchers report. The treatment, c...
Monthly News Roundup - February 2025
FDA Updates Izervay Label to Lengthen Treatment Duration for Geographic Atrophy Izervay (avacincaptad pegol) from Astellas is now FDA-approved without a limitation on duration of dosing, allowing...
Automated Insulin Delivery System Improves Glycemic Control in Youth
THURSDAY, Dec. 12, 2024 – Initiation of an automated insulin delivery (AID) system improves glycemic control in children and adolescents with type 1 diabetes (T1D), according to a study published in...
Novo Nordisk to Lower U.S. List Prices for Tresiba and Fiasp by More Than 70%
PLAINSBORO, N.J., Dec. 05, 2024 – Novo Nordisk today announced plans to reduce the US list prices of two insulin products by more than 70% to better meet the needs of people living with diabetes....
FDA Medwatch Alert: Novo Nordisk Issues Voluntary Nationwide Recall of Levemir, Tresiba, Fiasp, Novolog and Xultophy Product Samples Due to Improper Storage Temperature Conditions
May 10, 2021 – Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the consumer level. These products are b...
FDA Approves Fiasp (insulin aspart injection) for the Treatment of Children with Diabetes
PLAINSBORO, N.J., Jan. 6, 2020 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection) 100 u/mL for use as a new...
FDA Approves Fiasp (insulin aspart injection) for Use in Insulin Infusion Pumps for Adults with Type 1 or Type 2 Diabetes
PLAINSBORO, N.J., Oct. 22, 2019 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp (insulin aspart injection) 100 u/mL to...
FDA Medwatch Alert: Caution When Using Pen Needles to Inject Medicines: FDA Safety Communication
Audience: Patients and caregivers who use or are considering using pen injectors with pen needles to inject prescription medicines. Health care providers who treat patients, or who train...
Novo Nordisk Receives FDA Approval for Fiasp (insulin aspart injection), a New Fast-Acting Mealtime Insulin
PLAINSBORO, N.J., Sept. 29, 2017 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp (insulin aspart injection) 100 Units/mL, a fast-acting...
Further information
Related condition support groups
Diabetes, Type 2, Diabetes, Type 1